RIPK3 and alkaline phosphatase measurement: In terms of treatment, serum amyloid A (SAA) is a sensitive biomarker in the early stage of inflammatory diseases and studies have shown that SAA3 induces the RIPK3-dependent necroptosis pathway and leads to AP in acinar cells, which suggests that this pathway may be a potential drug target of AP [48].